Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Scibase

Related articles:
4/8/2024 5:18:18 AM - Scibase: Raises capital and strengthens owner base - Redeye - Redeye comments on today’s news. Scibase has resolved a directed issue of c SEK 33m and a rights issue of c SEK 15m or a total of SEK 48m before costs or c SEK 44m after costs. Both issues use the same subscription price of SEK 0.42 per unit, corresponding to SEK 0.42 per share. This is a more significant capital raise than the SEK 30m we had expected and thus corresponds to a slightly higher dilution than we accounted for. We see this as a positive move done at market price and adding a new solid owner base with a long-term potential upside in the warrants issued.
4/5/2024 7:35:26 AM - Scibase handelsstoppad på First North - Nasdaq har stoppat handeln i medicinteknikbolaget Scibase strax efter fredagens börsöppning. Innan dess hann det ske två avslut i aktien som noterar en nedgång på 5 procent för dagen.
2/28/2024 8:20:59 AM - Scibase: New Partnership in Barrier - Redeye - Redeye comments on Scibase’s new partnership within the Barrier field. The partnership with French Skinobs is a global platform for connecting researchers within cosmetic and medical research. The partnership is in line with what Scibase communicated earlier: they see a good opportunity in the cosmetic industry where several large cosmetic companies use Nevisense in their R&D. We see this partnership as a natural step to increase awareness in that industry. The recent study where a direct comparison between electrical impedance spectroscopy (EIS) using Nevisense and the commonly accepted trans-epidermal water loss (TEWL) measurement technique has, in our view, increased the interest in EIS method multiple times. The study clearly showed an advantage of using EIS as a method. The new partnership is complex to quantify in terms of sales potential, but we like that Scibase continues to expand its network for increased potential sales in the future.
2/21/2024 8:04:25 AM - Scibase Q4’23: Impressive gross margin while sales came in softer - Redeye - Redeye saw a Q4 report showing sales below our estimates, with a total growth of 16% for the quarter. Costs were higher than expected again, mainly driven by the marketing efforts that continue in the US. The gross margin was higher than expected at 73.5%. Adjusted for fx effects, it was still higher than expected at 72% vs. our estimate of 66%. The EBIT result was SEK -15.7m vs. our estimate of -11.7m; the higher marketing costs and R&D mostly drove the deviation. Growth continues excellently in Germany, while US sales have also shown good growth, although at low absolute levels.
1/12/2024 7:14:46 AM - Scibase: CEO update – first 100 days - Redeye - Redeye comments on the business update by CEO Pia Renaudin after the initial 100 days at Scibase. In general, a positive outlook, in our view, highlights the positive steps taken to transition into a fully commercial company. There is a clearer picture of how the strategy regarding reimbursement is panning out in the significant US market.
11/20/2023 6:11:15 AM - Scibase: Entering sunny California - Redeye - Redeye views favorably the news that Scibase has entered into a collaboration with the Skin and Cancer Institute for a pilot test in some clinics in California. This dermatology network will be the first in California to use AI-based technology for skin cancer detection. This network has over 50 clinics across three states in the country’s west. (California, Arizona, Nevada). The entrance into this collaboration opens up possibilities in one of the larger markets in the US, which is exciting. It opens up Nevisense to new US payers, thus driving awareness. We view this positively as a natural growth opportunity in the future. We have expected that Scibase would expand in the US, with a new CEO with experience relating to that market and staffing up in general in the US operation. All in all, positive steps from Scibase on the significant US market.
11/13/2023 6:21:12 AM - Scibase: Increased focus on sales development - Redeye - Redeye saw a Q3 report that was both better and weaker than expected. Sales beat expectations paired with higher costs, producing lower results than expected. The German market continues to shine while we await a real breakthrough in the US due to the slow reimbursement process. We have adjusted our estimates for 2024/25e due to the slower US development and added an equity issue in our model. The dilutive effect is the primary reason for the lowered Based case to SEK 4.3(6.8) per share.
11/10/2023 8:02:13 AM - Scibase Q3’23: First take – record electrode sales - Redeye - Redeye saw a Q3 report showing sales above our estimates, with a total growth of 47% for the quarter. Costs were again higher than expected, mainly driven by the marketing efforts that were picking up in the US. The gross margin was higher than expected at 68%, although adjusted for fx effects, it aligned more with our expectation at 65% vs our estimate of 66%. The EBIT result was SEK -12.7m vs. our estimate of -11m; the higher marketing costs mostly drove the deviation. Growth continues at a really good pace in Germany, while US sales were still hampered in the quarter by delays in the Medicare fee schedule review.
9/29/2023 6:36:41 AM - Scibase: Further positive results in Barrier study - Redeye - Redeye comments on the second published study in two days regarding the Skin Barrier field from Scibase.
9/28/2023 7:06:08 AM - Scibase: Interesting clinical results within Barrier/AD - Redeye - Redeye is encouraged by the publication of the clinical results from a study at the University Children’s Hospital in Zürich.
9/25/2023 9:51:01 AM - Scibase: Important pilot in Texas - Redeye - Redeye is favorable to the initiation of a new pilot with Bare Dermatology based in Texas.
9/4/2023 7:55:50 AM - Scibase: Strengthening the US operations - Redeye - Redeye is positive that Scibase has hired Dan Walker to become VP of US commercial operations. Mr Walker has extensive experience in the Dermatology sector and has been with Biofrontera for more than seven years, most recently as Senior Director. The move by Scibase to strengthen its US operations is positive as a large part of the potential lies in the US, and the experience brought by the new hire is highly valuable to Scibase. There have been a lot of positive developments in the US during the last 12 months. However, the sales development has not been as expected. This move is therefore a positive to start to accelerate sales.
8/30/2023 5:34:01 AM - Scibase: New CEO appointed - Redeye - Redeye’s short comment on the new CEO appointment.
8/21/2023 5:30:02 AM - Scibase Q2’23: Germany is showing strength with the US breakthrough to come - Redeye - Redeye saw a Q2 report that was slightly weaker on the top line, with higher costs, making for a lower outcome than expected. The German market continues to develop well while we await a real breakthrough in the US, as the reimbursement process has been slow. We believe it is more of a timing issue than a real one. We have adjusted our estimates and left our fair value range unchanged but lowered our Base case slightly as we still see excellent growth opportunities going forward.
8/18/2023 6:59:32 AM - Scibase Q2’23: First take – Strong development in Germany - Redeye - Redeye saw a Q2 report showing sales slightly below our estimates in real terms, with a total growth of 36% for the quarter. Costs were higher as marketing efforts were picking up in the US. The gross margin aligned with our expectation of just above 65%. The EBIT result was SEK -13.8m vs. our estimate of -9.1m; the higher marketing costs mostly drove the deviation. Growth continues at a good pace in Germany, while US sales were still hampered in the quarter by delays in the Medicare fee schedule review. Most important is the financing closing, adding SEK 70m during the quarter. We will likely only make small adjustments to our Fair value range and Base case.
6/19/2023 7:01:30 AM - Scibase: Good levels of reimbursement at two MACs in the US - Redeye - Redeye comments on the recent progress update from Scibase and our research into fee schedules for selected MACs in the US.
5/16/2023 6:54:59 AM - Scibase: Management change – no drama - Redeye - Redeye’s short comment on the announced management change.
5/11/2023 8:33:17 AM - SciBase: Germany shines and financing sorted - Redeye - Redeye saw a Q1 report that was slightly weaker than expected but not a material deviation. The German market continues to develop well and is profitable. The US delayed Medicare fee schedule review affected sales negatively in the quarter, but this issue has now been resolved. We have made small adjustments to our estimates and left our fair value range and Base case unchanged. With the financing sorted, the focus is now on the company's performance in the coming quarter.
5/11/2023 5:31:52 AM - SciBase: Germany shines and financing sorted - Redeye - Redeye saw a Q1 report that was slightly weaker than expected but not a material deviation. The German market continues to develop well and is profitable. The US delayed Medicare fee schedule review affected sales negatively in the quarter, but this issue has now been resolved. We have made small adjustments to our estimates and left our fair value range and Base case unchanged. With the financing sorted, the focus is now on the company's performance in the coming quarter.
5/10/2023 7:19:51 AM - Scibase Q1’23: First take – Excellent gross margin and financing sorted - Redeye - Redeye saw a Q1 report showing sales slightly below our estimates in real terms, while costs were generally in line. A strong gross margin had a positive effect. The EBIT result at SEK -10.8m vs our estimate of -9.3m. Growth continues at a good pace in Germany, while US sales were hampered by delays in the Medicare fee schedule review, which now has been sorted. Most important is the financing closing, adding SEK 70m after the quarters end. We will most likely only make minor adjustments to our Fair value range and Base case.
4/4/2023 7:20:32 AM - Scibase: Positive news from the US - Redeye - Redeye views positively the news that two Medicare Administrative Contractors (MACs) have updated their fee schedules for Scibase’s early detection test for melanoma. The company has long awaited this and gives a welcome push in the ongoing US expansion.
2/14/2023 6:40:55 AM - Scibase: Securing growth capital - Redeye - Redeye updates the fair value range after the Q4 report and the share issue. The fair value range and Based case changes are temporary and could be altered depending on the outcome of the share issue. We do not, however, expect the value difference to be substantial after the outcome in March.
2/13/2023 7:59:51 AM - Scibase Q4’22: First take – results in line – large share issue announced - Redeye - Redeye saw a Q4 report showing sales roughly in line with estimates, while costs were slightly higher, giving an EBIT result at SEK -13.6m vs. -12.2m. The more important news is the announcement of a large share issue to secure financing going forward. We will adjust our Fair value range and Base case accordingly.
11/10/2022 8:40:47 AM - Scibase Q3’22: Sales progress in the quarter - Redeye - Redeye continues to see a very compelling ling term investment case. Scibase's Q3 results were mixed with higher sales than expected and higher costs. We make minor adjustments to our estimates and leave our Base case unchanged at SEK 11 per share.
11/8/2022 6:14:20 AM - Scibase: New collaboration a great step towards validation - Redeye - Redeye is encouraged by the news that Scibase has entered into a collaboration with Johnson & Johnson to detect skin barrier and predict atopic dermatitis in children. This is an excellent step towards validating the AI-based solution based on Scibase technology.
10/26/2022 8:24:27 AM - SciBase: Further support for Nevisense from a study - Redeye - Redeye is positive as regards the results from a new study, further showing statistically significant improvement regarding correct biopsies choice when adding Nevisense results to the standard of care visual and dermoscopy.
10/10/2022 5:54:14 AM - SciBase: Barrier a future Growth driver - Redeye - Redeye updates our expectations on melanoma and NMSC and includes Barrier detection to our estimates for SciBase as we now see a real long-term opportunity in this field. Current share price levels do not reflect the long-term potential.
9/9/2022 10:10:21 AM - Scibase: Encouraging news around Nevisense Barrier detection - Redeye - Redeye views with interest the news regarding the Nevisense and EIS to assess the effect of commercial laundry detergents on the skin barrier.
9/5/2022 5:31:05 AM - Scibase: Encouraging news around Nevisense Barrier detection - Redeye - Redeye views with interest the news regarding the Nevisense and EIS to assess the effect of commercial laundry detergents on the skin barrier.
8/19/2022 6:27:54 AM - Scibase Q2: Very strong gross margin development - Redeye - Redeye continues to see an interesting long term investment case. Scibase’s Q2 results were generally in line, albeit with a slightly lower sales number than expected. The item that stood out most in the quarter was the record-strong gross margin. We leave our Base case unchanged at SEK 12 per share.
8/18/2022 7:15:12 AM - Scibase Q2: First take - Redeye - Redeye saw a Q2 report showing strong growth and a record high gross margin at 70%.
5/13/2022 7:03:31 AM - Scibase: Strong start to the year - Redeye - Redeye changes our short-term estimates slightly because of a better outcome than expected in the first quarter. The sales development was strong and a healthy gross margin was reported. The costs were in line apart from higher R&D costs. We reiterate our Base case at SEK 12 per share and unchanged fair value range of SEK 5 – 20 per share.
5/12/2022 7:09:40 AM - Scibase Q1’22: First take - Redeye - Redeye saw a Q1 report that showed stronger growth and a higher gross margin than expected. Real sales progress in the US and a strong order book going into Q2 are highlights.
2/28/2022 8:14:44 AM - Scibase: Underlying positive Signs - Redeye - Redeye continues to see progress for Scibase in the Q4 report. We marginally adjust our estimates downwards for the current year on the back of higher costs and a somewhat uncertain market in the first quarter. We maintain our fair value range and base case.
2/23/2022 8:36:54 AM - Scibase Q4’22: Strong signal from the US - Redeye - Redeye sees a Q4 report in line with our sales expectations. The costs were higher than expected primarily due to higher sales activities, which is beneficial in driving growth in 2022. The financial position is solid. We do not expect to revise our expectations for 2022 significantly.
1/26/2022 8:06:23 AM - Scibase: Confirmation of confidence in Study - Redeye - Redeye comments on a newly published pilot study, further confirming the strength of the Nevisense device.
12/22/2021 8:29:09 AM - Scibase: Payment request submitted - Redeye - Redeye comments on Scibase submitting a request for an appropriate payment assignment for Medicare to NGS.
12/16/2021 8:30:29 AM - Scibase: Encouraging news - Redeye - Redeye is encouraged by the news that Scibase has received an additional order from Advanced Dermatology P.C. as it proves that the model works.
11/12/2021 8:33:29 AM - Scibase: Strong outlook for 2022 - Redeye - Redeye sees progress in all important aspects for Scibase in the Q3 report. We adjust our estimates upwards for the current year on the back of slightly better results and increase our fair value range and base case.
11/11/2021 10:21:35 AM - Scibase Q3’21: Initial take - Redeye - Redeye sees a report very much in line with expectations. The important processes around reimbursement are proceeding as planned.
8/20/2021 8:40:47 AM - Scibase: Q2’21, Our Conviction unchanged - Redeye - Redeye continues to view Scibase in a positive light after the Q2 report yesterday. We still see a foundation for strong future growth. There has been progress on several fronts during 2021, and we expect a positive news flow in H2'21 and 2022. After a report in line with our expectations and a promising outlook, we maintain our base case's motivated value at SEK 11 per share.
8/19/2021 7:16:50 AM - SciBase Q2’21: Initial take - Redeye - Redeye's first comments on Scibase's Q2 report. The sales were slightly lower than expected; however, the sales levels are still small, and we are encouraged by the increased levels of electrode sales. Costs were somewhat higher than expected. A higher license fee for ASIC development and increased activity levels in the US is behind this. We will make minor revisions based on the report and do not expect the motived value to change materially.
6/3/2021 6:39:17 AM - Investeringsansvarig på Van Herk: Vi lägger ingen vikt vid kortsiktiga sentimentssvängningar - Den holländska investeringsfirman Van Herk med styrelseposter i bland annat Bioinvent och Immunicum investerar på lång sikt och lägger därmed ingen större vikt vid sentimentssvängningar inom life science-sektorn. Den senaste investeringen i det svenska First North-bolaget Scibase var självklar. Det säger investeringsansvarige Dharminder Chahal i en intervju.
5/31/2021 11:17:17 AM - Scibase: Cash infusion to drive growth - Redeye - Redeye's take on the two directed issues communicated this morning. These two issues will bring in SEK 71,2m before costs with an 11% discount.
5/14/2021 7:20:03 AM - Scibase Positive News flow - Redeye - Redeye maintains its optimistic view on SciBase following the Q1 report. The report was in line with our expectations. The company is now with the MDR passed, and the upcoming reimbursement in the US set up to take the next step that will drive growth into 2022. After looking deeper into the reimbursement levels, we have increased our price assumptions in the US from 2022. This leads to higher estimates from 2022 and onwards. With the forecast changes that affect the long-term growth, we raise our Base case fair value to SEK 11 per share. This implies a significant potential from current share price levels.
5/14/2021 6:14:03 AM - Scibase Q1: Report in line - Redeye - Redeyes first comments on the Q1 report.
5/10/2021 3:47:32 PM - Scibase: Important MDR Certification passed as Expected - Redeye - Redeye comments on the MDR certification.
5/4/2021 7:26:32 AM - Scibase: The first application for Medicare reimbursement - Redeye - Redeye views the news that Scibase has sent in its first application for reimbursement from Medicare filed in Florida as highly positive. This is an essential step in the process of receiving reimbursement in Florida. The timing was earlier than we expected and opens up for a potential positive outcome already in the second half of 2021.
4/12/2021 7:20:13 AM - Scibase: Platform strength evident - Redeye - Redeye views favorably on yet another positive study, this time regarding the skin barrier and atopic dermatitis (AD). The study performed by the Swiss Institute of Allergy and Asthma Research (SIAF) shows excellent results by using Nevisense to characterize the skin barrier in atopic dermatitis.
12/8/2020 9:09:17 AM - Ny studie publicerad som validerar Scibases Nevisense inom icke-melanom hudcancer - En ny studie från Tyskland har publicerats som uppges validera Scibases Nevisense inom icke-melanom hudcancer, som är betydligt vanligare än malignt melanom. Det framgår av ett pressmeddelande.
11/13/2020 10:24:05 AM - Scibase: Closing the valuation gap driven by 90% likelihood of achieving US reimbursement - Vator - Obtaining payment for medtech products from government bodies and private insurance companies is generally not a clear-cut route, and breaking into the US market is key for medtech companies to drive sales growth. Challenges is this area are common reasons why early-stage commercial medtech companies become stranded; consequently, some investors avoid these early-stage companies prior to them showing traction in the payor process. The flip side to this exact same coin is the good news; the stock market rewards medtech companies handsomely when they break through, unlock payor coverage, and deliver consecutive commercial advances translating into steady sales growth.
11/13/2020 10:13:03 AM - Scibase har de nödvändiga förutsättningarna för att öka tillväxten, riktkurs 7,5 kronor - Vator Securities - Scibase bedöms ha de nödvändiga förutsättningarna för att öka tillväxten på omsättningsraden, förklarar analysfirman Vator Securities i en uppdragsanalys där man sätter riktkursen till 7,5 kronor.
11/12/2020 7:21:12 AM - Scibase ökar omsättning och minskar förlusten under 'milstolpekvartal' - Scibase redovisar ökande omsättning under tredje kvartalet jämfört med samma period året innan. Rörelseförlusten minskade.
11/4/2020 8:02:30 AM - Scibase tar in produktions- och logistikansvarig till ledningsgruppen - Scibase uppger att Linn Olsen, som är ansvarig för produktion och logistik, skall bli en del av ledningsgruppen. Det förmedlas via ett pressmeddelande.
11/2/2020 8:12:32 AM - Scibase har beviljats kategori III CTP-kod i USA för Nevisense - Scibase har i USA beviljats en kategori III CPT-kod av American Medical Association för Nevisense melanom detektionstest. Det framgår av ett pressmeddelande.
10/30/2020 8:00:36 AM - Scibase lanserar Nevisense Go - Scibase lanserar det handhållna och bärbara instrumentet Nevisense Go. Produkten är baserad på bolagets nya teknologiplattform och är en uppföljare till Nevisense för melanomdetektion som var en av de första AI-baserade produkterna att godkännas för kliniskt bruk.
10/21/2020 9:16:35 AM - Scibase tillförs 31,9 miljoner kronor genom teckningsoptioner, nyttjandegrad om 91,4 procent - Scibase uppger att de tillförts 31,9 miljoner kronor före emissionskostnader genom nyttjandet av teckningsoptioner. Nyttjandegraden blev totalt 91,4 procent, enligt ett pressmeddelande.
10/2/2020 6:13:26 AM - Scibase lösenpris för teckningsoptioner av serie TO1 fastställts till 1,75 kronor - Scibase lösenpris för utnyttjande av teckningsoptioner av serie TO1 har fastställts till 1,75 kronor. Det framgår av ett pressmeddelande.
9/29/2020 6:58:59 AM - Återhämtning i USA och Tyskland under sommaren, hoppas kunna nå ett av målen för 2020 - Scibases vd - Scibases basverksamhet kring Nevisense-tester såg en återhämtning på marknaderna i USA och Tyskland i sommar efter den negativa påverkan från covid-19. Det uppger vd Simon Grant i senaste nyhetsbrevet.
9/16/2020 6:09:02 AM - Scibase meddelar att nya kliniska studier visar förbättrad detektion med Nevisense - Scibase meddelar att nya kliniska studier visar förbättrad detektion av melanom för amerikanska läkare med Nevisense.
8/26/2020 6:36:21 AM - Scibases Nevisense är inkluderad i barnstudie i New York - Scibase, som är specialiserade på AI rörande hudåkommor, meddelar att Nevisense kommer att vara del av en klinisk studie som löper parallellt med ACTIVATE-studien (sponsrad av Immune Tolerance Network och NIAID/NIH). Studien drivs av avdelningen för pediatrisk allergi vid Mount Sinai sjukhuset i New York.
8/20/2020 6:41:00 AM - Scibase minskar omsättning men även förlusten under andra kvartalet - Scibase redovisar minskande omsättning under andra kvartalet jämfört med samma period året innan. Bolaget rapporterar minskad nettoförlust.
8/18/2020 6:15:50 AM - Scibases Nevisense med i amerikansk studie - Scibase första produkt Nevisense kommer att inkluderas i en stor klinisk studie initierad av The Ronald O. Perelman Department of Dermatology clinic vid NYU Langone Health.
7/24/2020 6:54:53 AM - Hög aktivitet hos Scibase, förväntar sig nivån hålls under hela året - vd - Aktivitetsnivån har varit hög aktivitet hos Scibase och bolaget förväntar sig att nivån hålls under hela året. Det framgår av ett vd-brev till aktieägarna.
3/30/2020 4:34:05 PM - USAs Dallas FED index minskade mer än väntat i mars - USAs Dallas FED index minskade mer än väntat i mars
2/19/2020 3:13:28 PM - Börsplus behåller sitt köpråd för Bahnhof efter bokslutet - Börsplus behåller sitt köpråd för Bahnhof efter bokslutet
2/19/2020 3:13:10 PM - K2A ökade förvaltningsresultat under fjärde kvartalet - K2A ökade förvaltningsresultat under fjärde kvartalet
2/19/2020 8:02:55 AM - Boeing ska undersöka främmande föremål i 737 Max - Boeing ska undersöka främmande föremål i 737 Max
2/17/2020 2:25:02 PM - Lundin Petroleum bygger första vindkraftsparken i Finland – Di - Lundin Petroleum bygger första vindkraftsparken i Finland – Di
2/12/2020 9:22:44 AM - Budgivaren Ograi Bidco vill möblera om rejält i styrelsen i Opus - Budgivaren Ograi Bidco vill möblera om rejält i styrelsen i Opus
2/12/2020 8:53:07 AM - Heineken ökar omsättning och rörelseresultat under helåret 2019, byter vd till sommaren - Heineken ökar omsättning och rörelseresultat under helåret 2019, byter vd till sommaren
2/11/2020 5:39:25 PM - Coor väntas redovisa 102 miljoner kronor i rörelseresultat i fjärde kvartalet – Factset konsensus - Coor väntas redovisa 102 miljoner kronor i rörelseresultat i fjärde kvartalet – Factset konsensus
2/11/2020 4:07:33 PM - Arden X ökade 3,5 procent i januari – Stillfront förvärvade Storm8 för 2,9 miljarder kronor - Arden X ökade 3,5 procent i januari – Stillfront förvärvade Storm8 för 2,9 miljarder kronor
2/11/2020 3:29:39 PM - Lohilo Foods ökar omsättning men minskar nettoresultat under helåret 2019 - Lohilo Foods ökar omsättning men minskar nettoresultat under helåret 2019
2/11/2020 3:03:48 PM - Kalender onsdag 12 februari - Kalender onsdag 12 februari
2/11/2020 1:13:58 PM - ING ser ingen större påverkan på kronan vid Riksbankens räntebeslut - ING ser ingen större påverkan på kronan vid Riksbankens räntebeslut
2/10/2020 11:03:25 AM - Aker BP väntas redovisa redovisa 746 miljoner dollar i ebitda-resultat i fjärde kvartalet – Factset konsensus - Aker BP väntas redovisa redovisa 746 miljoner dollar i ebitda-resultat i fjärde kvartalet – Factset konsensus
2/10/2020 10:01:09 AM - Intu bekräftar att det diskuterar en miljardemission med storägarna - Intu bekräftar att det diskuterar en miljardemission med storägarna
2/10/2020 9:35:32 AM - Lannebo Teknik Småbolag vinnare när storinnehav får bud från Atlas Copco - Lannebo Teknik Småbolag vinnare när storinnehav får bud från Atlas Copco
1/29/2020 2:02:32 PM - Victoria Secrets grundare kan avgå som vd och sälja delar av eller hela märket – WSJ - Victoria Secrets grundare kan avgå som vd och sälja delar av eller hela märket – WSJ
1/29/2020 11:23:14 AM - Getinge väntas redovisa 945 miljoner kronor i nettoresultat i fjärde kvartalet – Factset konsensus - Getinge väntas redovisa 945 miljoner kronor i nettoresultat i fjärde kvartalet – Factset konsensus
1/29/2020 8:37:47 AM - Stark försäljning för modehuset SMCP i fjärde kvartalet, upprepar årsprognosen - Stark försäljning för modehuset SMCP i fjärde kvartalet, upprepar årsprognosen
1/10/2020 2:02:54 PM - Tesla-rally kan förbytas till djup pessimism – strateg - Tesla-rally kan förbytas till djup pessimism – strateg
1/8/2020 3:03:47 PM - Kalender torsdag 9 januari - Kalender torsdag 9 januari
1/2/2020 9:47:50 AM - Italiens inköpschefsindex för industrin minskade mer än väntat i december - Italiens inköpschefsindex för industrin minskade mer än väntat i december
12/10/2019 11:32:31 AM - Grab lanserar förbetalt bankkort i partnerskap med Mastercard - Grab lanserar förbetalt bankkort i partnerskap med Mastercard
11/1/2019 10:49:22 AM - BHP Group investerar i uppstart av katastrofdrabbad verksamhet - BHP Group investerar i uppstart av katastrofdrabbad verksamhet
10/3/2019 10:03:19 AM - Dåligt glid för Skistar-aktien som faller 7 procent efter bokslutsrapporten - Dåligt glid för Skistar-aktien som faller 7 procent efter bokslutsrapporten
10/2/2019 11:22:31 AM - Ecorubs vd återfår aktier som lånats ut till Bracknor - Ecorubs vd återfår aktier som lånats ut till Bracknor
10/2/2019 7:55:53 AM - Tesla har köpt startupen Deepscale – CNBC - Tesla har köpt startupen Deepscale – CNBC
10/1/2019 3:04:34 PM - Kalender onsdag 2 oktober - Kalender onsdag 2 oktober
8/29/2019 8:02:08 AM - Aktiespararen ger köpråd för Bravida, Traton, GHP och Alfa Laval samt säljråd för Feelgood - Aktiespararen ger köpråd för Bravida, Traton, GHP och Alfa Laval samt säljråd för Feelgood
8/26/2019 4:12:38 PM - Skandia Småbolag Sverige backade i juli – lyfter upp TF Bank och Enea - Skandia Småbolag Sverige backade i juli – lyfter upp TF Bank och Enea
8/26/2019 3:05:11 PM - Kalender tisdag 27 augusti - Kalender tisdag 27 augusti
8/26/2019 2:14:39 PM - Didner & Gerge Småbolag sjönk 1,7 procent i juli - Didner & Gerge Småbolag sjönk 1,7 procent i juli
8/26/2019 1:46:46 PM - Didner & Gerge Global utvecklades positivt i juli med en uppgång på 4,4 procent - Didner & Gerge Global utvecklades positivt i juli med en uppgång på 4,4 procent
8/26/2019 9:11:15 AM - Blackrock diskuterar infrastrukturinvesteringar i Israel – BN - Blackrock diskuterar infrastrukturinvesteringar i Israel – BN
8/23/2019 8:32:08 AM - Svagt uppåt i Asien, Nikkei ökade 0,4 procent - Svagt uppåt i Asien, Nikkei ökade 0,4 procent
8/21/2019 2:02:10 PM - Obstecare ökar intäkterna samtidigt som förlusten steg i andra kvrtalet - Obstecare ökar intäkterna samtidigt som förlusten steg i andra kvrtalet
8/6/2019 3:32:13 PM - Amazon sänker studentpriset på sin musiktjänst till 99 cent i månaden - Amazon sänker studentpriset på sin musiktjänst till 99 cent i månaden
7/15/2019 2:32:11 PM - USAs Empire tillverkningsindex ökade mer än väntat i juli - USAs Empire tillverkningsindex ökade mer än väntat i juli
6/10/2019 6:33:14 AM - Kalender måndag 10 juni - Kalender måndag 10 juni
5/16/2019 10:32:31 AM - Stor sannolikhet för expansion av hälsovårdssystemet i USA, ganska höga värderingar inom sektorn för cannabisläkemedel – Rhenman Healthcare Equity L/S - Stor sannolikhet för expansion av hälsovårdssystemet i USA, ganska höga värderingar inom sektorn för cannabisläkemedel – Rhenman Healthcare Equity L/S
5/6/2019 10:02:23 AM - Stocks in Play – Gunnebo stiger på köpråd från Di - Stocks in Play – Gunnebo stiger på köpråd från Di
4/29/2019 11:02:33 AM - EMUs konjunkturindikator minskade mer än väntat i april - EMUs konjunkturindikator minskade mer än väntat i april
4/29/2019 10:02:30 AM - Fortsatt förlust för Weareqiiwi i första kvartalet – Wordington har passerat 0,2 miljoner kronor spelare - Fortsatt förlust för Weareqiiwi i första kvartalet – Wordington har passerat 0,2 miljoner kronor spelare
4/29/2019 8:02:35 AM - Finlands konsumentförtroende minskade i april - Finlands konsumentförtroende minskade i april
4/23/2019 3:32:30 PM - Victoria Park rapporterar ett ökande nettoresultat på 490 miljoner kronor - Victoria Park rapporterar ett ökande nettoresultat på 490 miljoner kronor
4/18/2019 6:32:25 AM - Kalender torsdag 18 april - Kalender torsdag 18 april
3/26/2019 1:32:11 PM - Majoriteten av bitcoin-handeln är falsk – Bitwise - Majoriteten av bitcoin-handeln är falsk – Bitwise
3/21/2019 3:32:16 PM - Evli Nordic steg 3,5 procent i februari, gynnades av att inte vara investerad i Swedbank - Evli Nordic steg 3,5 procent i februari, gynnades av att inte vara investerad i Swedbank
3/20/2019 2:32:13 PM - Danske Invest Lux Europe High Dividend steg i linje med jämförelseindex, räknar med att minska exponeringen något i år - Danske Invest Lux Europe High Dividend steg i linje med jämförelseindex, räknar med att minska exponeringen något i år
10/11/2018 10:32:00 AM - Katzenbergs tv-projekt får namnet Quibi - Katzenbergs tv-projekt får namnet Quibi